SABCS 2022 | Anti-HER2 CAR macrophages for solid tumors

Yara Abdou, MD, UNC School of Medicine, Chapel Hill, NC, discusses the use of adoptive cell therapies in breast cancer, and the associated challenges. For CAR-T cell therapy, a significant challenge is poor infiltration into solid tumors, which could be overcome by using potent stimulation of antigen presenting cells. CAR macrophages have recently been shown to be able to traffic the tumors, phagocytose tumor cells and reprogram the tumor microenvironment (TME) to stimulate an adaptive immune response. Pre-clinical models have demonstrated anti-HER2 CAR macrophages to decrease tumor burden and increase survival in mice with HER2-expressing tumors. This led to the first in-human Phase I trial (NCT04660929) to evaluate the safety and preliminary efficacy of an anti-HER2 CAR in patients with metastatic solid tumors overexpressing HER2. This interview took place at the San Antonio Breast Cancer Symposium (SABCS) 2022 in San Antonio, TX.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.